Table 4.
Falls / 1,000 Exposed Days | Falls / 1,000 Unexposed Days | Unadjusted HRa [95% CI] | Adjusted HRb [95% CI] | |
---|---|---|---|---|
Age < 65 (N = 141,393) | ||||
Benzodiazepine | 3.6 | 1.2 | 2.6 [2.3–3.0] | 2.0 [1.8–2.3] |
BZRA | 2.7 | 1.7 | 1.4 [1.2–1.8] | 1.4 [1.1–1.7] |
Trazodone | 3.3 | 1.7 | 1.7 [1.4–2.2] | 1.2 [0.99–1.5] |
Diphenhydramine | 2.4 | 1.7 | 1.2 [1.02–1.5] | 1.3 [1.03–1.5] |
Atypical antipsychotic | 5.2 | 1.6 | 2.9 [2.5–3.4] | 1.6 [1.4–1.9] |
Age ≥ 65 (N = 84,105) | ||||
Benzodiazepine | 3.5 | 2.3 | 1.4 [1.2–1.6] | 1.4 [1.2–1.6] |
BZRA | 3.6 | 2.4 | 1.4 [1.1–1.8] | 1.7 [1.3–2.1] |
Trazodone | 3.3 | 2.4 | 1.3 [1.03–1.6] | 1.2 [0.98–1.5] |
Diphenhydramine | 2.7 | 2.4 | 1.0 [0.8–1.4] | 1.1 [0.8–1.6] |
Atypical antipsychotic | 5.6 | 2.2 | 2.3 [2.0–2.7] | 1.6 [1.3–1.9] |
aBased on a marginal Cox-type regression model, including only the medication of interest, modeled as a time-varying covariate, and accounting for repeated hospitalizations of the same patient using a robust sandwich estimator.
bBased on a marginal Cox-type regression model, including all variables in Table 1, and accounting for repeated hospitalizations of the same patient using a robust sandwich estimator.